CYTK
Cytokinetics, Incorporated NASDAQ Listed Apr 30, 2004$74.25
After hrs
$76.45
-0.60%
Mkt Cap $9.2B
52w Low $29.31
88.3% of range
52w High $80.20
50d MA $63.98
200d MA $58.16
P/E (TTM)
-9.7x
EV/EBITDA
-10.4x
P/B
—
Debt/Equity
-1.9x
ROE
119.0%
P/FCF
-14.3x
RSI (14)
—
ATR (14)
—
Beta
0.48
50d MA
$63.98
200d MA
$58.16
Avg Volume
1.9M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
350 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -1.67 | -1.67 | +0.0% | 77.09 | +1.7% | -2.9% | -3.6% | — | — | — | — |
| Feb 24, 2026 | AMC | -1.48 | -1.50 | -1.4% | 70.10 | -2.8% | -10.3% | -10.7% | -11.2% | -12.4% | -13.4% | — |
| Nov 5, 2025 | AMC | -1.59 | -1.54 | +3.1% | 59.19 | -0.6% | +1.9% | +1.6% | +5.1% | +12.4% | +11.4% | — |
| Aug 7, 2025 | AMC | -1.34 | -1.12 | +16.4% | 35.25 | +1.7% | -3.2% | -5.7% | -2.7% | +4.6% | +9.8% | — |
| May 6, 2025 | AMC | -1.41 | -1.36 | +3.5% | 33.97 | +4.0% | -2.7% | -4.4% | -6.7% | -5.4% | -9.9% | — |
| Feb 27, 2025 | AMC | -1.29 | -1.26 | +2.3% | 47.45 | -6.5% | -3.1% | -9.6% | -7.9% | -7.5% | -8.8% | — |
| Nov 6, 2024 | AMC | -1.27 | -1.36 | -7.1% | 55.50 | -0.9% | +0.6% | +4.5% | +5.6% | +1.2% | +0.8% | — |
| Aug 8, 2024 | AMC | -1.02 | -1.31 | -28.4% | 54.00 | -3.7% | +3.3% | +4.0% | +3.8% | +3.5% | +5.7% | — |
| May 8, 2024 | AMC | -1.16 | -1.33 | -14.7% | 65.27 | +4.5% | -1.9% | -4.9% | -11.3% | -9.1% | -7.3% | — |
| Feb 27, 2024 | AMC | -1.03 | -1.38 | -34.0% | 80.99 | -3.8% | -9.8% | -10.8% | -8.7% | -16.4% | -18.0% | — |
| Nov 2, 2023 | AMC | -0.72 | -1.35 | -87.5% | 34.64 | +2.3% | +4.8% | -0.6% | +3.5% | +0.3% | -4.4% | — |
| Aug 3, 2023 | AMC | -1.23 | -1.34 | -8.9% | 31.70 | +0.9% | +4.7% | -1.1% | +0.8% | +0.3% | +2.5% | — |
| May 4, 2023 | AMC | -1.24 | -1.38 | -11.3% | 39.29 | +4.3% | +0.4% | -2.2% | -1.1% | -0.2% | -3.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Barclays | Maintains | Overweight → Overweight | — | $66.73 | $66.09 | -1.0% | -2.7% | -1.9% | -1.4% | -3.2% | -2.6% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $62.13 | $61.50 | -1.0% | +0.1% | +1.3% | -0.7% | -1.9% | -3.4% |
| Mar 17 | JP Morgan | Maintains | Overweight → Overweight | — | $60.83 | $60.94 | +0.2% | +2.1% | +2.2% | +3.5% | +1.4% | +0.2% |
| Mar 6 | UBS | Maintains | Neutral → Neutral | — | $62.19 | $61.38 | -1.3% | -2.9% | +0.4% | +3.2% | +2.3% | -3.5% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $62.89 | $62.61 | -0.4% | -0.4% | -1.1% | -2.3% | -3.5% | -1.0% |
| Feb 25 | Citizens | Maintains | Market Outperform → Market Outperform | — | $70.10 | $68.12 | -2.8% | -10.3% | -10.7% | -11.2% | -12.4% | -13.4% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $70.10 | $68.12 | -2.8% | -10.3% | -10.7% | -11.2% | -12.4% | -13.4% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $67.83 | $67.72 | -0.2% | +0.2% | +0.6% | +3.3% | -7.3% | -7.7% |
| Feb 3 | Truist | Maintains | Buy → Buy | — | $65.16 | $65.86 | +1.1% | -0.7% | -2.5% | -7.6% | -4.3% | -2.8% |
| Jan 21 | B. Riley Securities | Maintains | Buy → Buy | — | $63.78 | $64.69 | +1.4% | -1.2% | +1.8% | -0.6% | -0.9% | +0.4% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $63.78 | $64.69 | +1.4% | -1.2% | +1.8% | -0.6% | -0.9% | +0.4% |
| Jan 20 | JP Morgan | Maintains | Overweight → Overweight | — | $62.58 | $61.89 | -1.1% | +1.9% | +0.7% | +3.8% | +1.3% | +1.0% |
| Dec 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $65.60 | $64.97 | -1.0% | -3.5% | -2.2% | -3.8% | -5.9% | -6.4% |
| Dec 22 | Barclays | Maintains | Overweight → Overweight | — | $62.72 | $64.00 | +2.0% | +4.6% | +0.9% | +2.3% | +0.6% | -1.5% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.72 | $64.00 | +2.0% | +4.6% | +0.9% | +2.3% | +0.6% | -1.5% |
| Dec 22 | RBC Capital | Maintains | Outperform → Outperform | — | $62.72 | $64.00 | +2.0% | +4.6% | +0.9% | +2.3% | +0.6% | -1.5% |
| Dec 22 | Citizens | Maintains | Market Outperform → Market Outperform | — | $62.72 | $64.00 | +2.0% | +4.6% | +0.9% | +2.3% | +0.6% | -1.5% |
| Dec 22 | Needham | Maintains | Buy → Buy | — | $62.72 | $64.00 | +2.0% | +4.6% | +0.9% | +2.3% | +0.6% | -1.5% |
| Dec 19 | Goldman Sachs | Upgrade | Neutral → Buy | — | $62.20 | $62.93 | +1.2% | +0.8% | +5.5% | +1.8% | +3.2% | +1.5% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $60.77 | $60.99 | +0.4% | +4.2% | +2.3% | +2.1% | -1.6% | +2.4% |
| Nov 11 | RBC Capital | Maintains | Outperform → Outperform | — | $62.20 | $62.16 | -0.1% | +6.9% | +6.0% | +5.3% | +6.8% | +7.6% |
| Nov 10 | B. Riley Securities | Maintains | Buy → Buy | — | $60.16 | $60.30 | +0.2% | +3.4% | +10.5% | +9.6% | +8.9% | +10.4% |
| Oct 6 | Barclays | Maintains | Overweight → Overweight | — | $56.97 | $57.87 | +1.6% | +6.4% | +5.6% | +6.8% | +5.9% | +5.4% |
| Oct 2 | BofA Securities | Maintains | Neutral → Neutral | — | $55.84 | $56.16 | +0.6% | +0.9% | +2.0% | +8.6% | +7.8% | +8.9% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.40 | $50.19 | -0.4% | +6.9% | +9.0% | +10.8% | +11.7% | +13.0% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.66 | $48.99 | +0.7% | -0.8% | -0.2% | -0.8% | -1.7% | +3.6% |
| Sep 22 | B. Riley Securities | Maintains | Buy → Buy | — | $48.66 | $48.99 | +0.7% | -0.8% | -0.2% | -0.8% | -1.7% | +3.6% |
| Sep 3 | Barclays | Maintains | Overweight → Overweight | — | $49.62 | $49.90 | +0.6% | +0.7% | +0.3% | +6.8% | +5.0% | +3.8% |
| Sep 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $49.62 | $49.90 | +0.6% | +0.7% | +0.3% | +6.8% | +5.0% | +3.8% |
| Sep 2 | Stifel | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +41.5% | +40.8% | +50.0% | +47.4% |
| Sep 2 | Needham | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +41.5% | +40.8% | +50.0% | +47.4% |
| Sep 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $35.33 | $44.91 | +27.1% | +40.4% | +41.5% | +40.8% | +50.0% | +47.4% |
| Sep 2 | Citigroup | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +41.5% | +40.8% | +50.0% | +47.4% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $35.25 | $35.85 | +1.7% | -3.2% | -5.7% | -2.7% | +4.6% | +9.8% |
| Jun 9 | JP Morgan | Maintains | Overweight → Overweight | — | $32.30 | $32.95 | +2.0% | +2.6% | +6.9% | +2.5% | +2.8% | +6.4% |
| May 29 | Mizuho | Maintains | Outperform → Outperform | — | $30.28 | $30.23 | -0.2% | +3.4% | +2.4% | +3.1% | +5.7% | +7.0% |
| May 14 | Needham | Maintains | Buy → Buy | — | $30.61 | $30.50 | -0.4% | -2.0% | -2.5% | +1.3% | +0.5% | +6.7% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $33.04 | $32.76 | -0.8% | -1.7% | -4.1% | -2.8% | -7.4% | -9.2% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $33.97 | $35.34 | +4.0% | -2.7% | -4.4% | -6.7% | -5.4% | -9.9% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $33.97 | $35.34 | +4.0% | -2.7% | -4.4% | -6.7% | -5.4% | -9.9% |
| May 2 | Needham | Maintains | Buy → Buy | — | $42.92 | $37.67 | -12.2% | -13.0% | -14.6% | -20.9% | -23.0% | -24.3% |
| May 2 | UBS | Maintains | Neutral → Neutral | — | $42.92 | $37.67 | -12.2% | -13.0% | -14.6% | -20.9% | -23.0% | -24.3% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.48 | $38.90 | -1.5% | -3.9% | -4.2% | -3.7% | +2.2% | +2.4% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.81 | $38.91 | -2.3% | -3.1% | -1.7% | -0.8% | -4.7% | -5.0% |
| Apr 15 | BofA Securities | Maintains | Neutral → Neutral | — | $39.81 | $38.91 | -2.3% | -3.1% | -1.7% | -0.8% | -4.7% | -5.0% |
| Apr 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $37.32 | $36.20 | -3.0% | +1.4% | +3.6% | +6.7% | +3.3% | +4.9% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $35.99 | $36.52 | +1.5% | -3.9% | +3.7% | +5.2% | +7.4% | +10.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.52 | $40.44 | -0.2% | -7.8% | -11.2% | -14.7% | -7.9% | -6.6% |
| Apr 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $40.25 | $39.43 | -2.0% | +0.7% | -7.2% | -10.6% | -14.1% | -7.3% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.45 | $44.36 | -6.5% | -3.1% | -9.6% | -7.9% | -7.5% | -8.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Malik Fady IbrahamOff | EVP Research & Development | Sell | 3,500 | $77.37 | $271K | 153,902 | -2.92% | — |
| May 5, 2026 | WIERENGA WENDELLDir | — | Sell | 4,032 | $75.00 | $302K | 32,637 | -2.92% | — |
| May 5, 2026 | HENDERSON JOHN TDir | — | Sell | 20,000 | $75.97 | $1.5M | 75,237 | -2.92% | — |
| May 5, 2026 | Lee SungOff | EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.8M | 63,221 | -2.92% | — |
| May 5, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875K | 58,555 | -2.92% | — |
| May 1, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.0M | 58,555 | +16.71% | — |
| Apr 30, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $949K | 58,555 | -0.97% | +16.13% |
| Apr 29, 2026 | Blum Robert IDir/Off | President & CEO | Sell | 7,500 | $59.62 | $447K | 407,830 | +7.37% | +25.61% |
8-K
Cytokinetics Inc. -- 8-K Filing
Cytokinetics' MYQORZO received regulatory approvals across the U.S., China, and Europe for symptomatic obstructive hypertrophic cardiomyopathy, with U.S. commercialization launching immediately and multiple pipeline catalysts expected through 2026.
Feb 24
8-K · 8.01
!! High
Cytokinetics Inc. -- 8-K 8.01: Material Event / Announcement
Cytokinetics received European Commission approval for MYQORZO (aficamten) to treat obstructive hypertrophic cardiomyopathy, expanding the company's commercial opportunities in a major market.
Feb 17
Data updated apr 25, 2026 4:28am
· Source: massive.com